Back to top
more

Surmodics (SRDX)

(Delayed Data from NSDQ)

$37.66 USD

37.66
184,435

+0.09 (0.24%)

Updated Nov 5, 2024 04:00 PM ET

After-Market: $37.66 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Products

Zacks News

PRA Health Unit to Offer Free Access to Metys COVID-19 Module

PRA Health's (PRAH) new module is likely to boost Data Solutions segment.

Bio-Rad Rides on International Expansion Amid Cost Concerns

Each of Bio-Rad's (BIO) key segments registers solid growth across three major geographies of America, Europe and Asia.

Hologic (HOLX) Posts Q2 Preliminary Results, Withdraws View

Investors remain optimistic with Hologic's (HOLX) balanced segmental preliminary revenue results for second-quarter fiscal 2020.

Here's Why You Should Add Surmodics to Your Portfolio Now

Investor confidence is high in Surmodics' (SRDX) stock,thanks to solid prospects.

SurModics (SRDX) Down 22.1% Since Last Earnings Report: Can It Rebound?

SurModics (SRDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Surmodics (SRDX) Q1 Earnings Beat Estimates, Revenues Miss

Surmodics' (SRDX) fiscal first-quarter earnings benefit from higher revenues, segmental growth and strong fiscal 2020 outlook.

SurModics (SRDX) Surpasses Q1 Earnings Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 266.67% and -0.89%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: SurModics (SRDX) Q1 Earnings Expected to Decline

SurModics (SRDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Surmodics (SRDX) Stock for Now

Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.

Here's Why You Should Hold on to Surmodics (SRDX) Stock Now

Surmodics (SRDX) is gaining from continued strength at Medical Devices unit and persistent efforts to boost R&D functionalities. However, weak performance at Surmodics' IVD unit remains a concern.

Surmodics (SRDX) Q4 Earnings and Revenues Beat Estimates

Surmodics (SRDX) continues to gain from core Medical Devices unit, which saw significant contribution from the SurVeil deal with Abbott in Q4.

SurModics (SRDX) Q4 Earnings and Revenues Surpass Estimates

SurModics (SRDX) delivered earnings and revenue surprises of 5.71% and 8.01%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

LabCorp (LH) Q3 Earnings Surpass Estimates, Tapers View

LabCorp (LH) impresses investors with third-quarter 2019 results on the robust performance of the Covance Drug Development segment.

Here's Why You Should Hold on to Abbott (ABT) Stock for Now

Investors continue to be optimistic about Abbott's (ABT) performance.

ResMed Upgrades Nasal Care by Introducing Cradle CPAP Mask

ResMed (RMD) revolutionizes sleep apnea treatment by introducing a hassle-free and easy-to-use mask.

Trina Mukherjee headshot

Medical Products Industry Outlook: Prospects Seem Promising

Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.

Here's Why You Should Hold on to Chemed (CHE) Stock Right Now

Investors continue to be optimistic about Chemed's (CHE) performance.

Organigram (OGI) Catches Eye: Stock Jumps 8.6%

Organigram (OGI) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.

Top Ranked Momentum Stocks to Buy for September 26th

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, September 26th

Will SurModics (SRDX) Gain on Rising Earnings Estimates?

SurModics (SRDX) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Nalak Das headshot

Wall Street Bulls Roaring Despite Slowdown Fears: 5 Top Picks

Year to date, the performance on Wall Street is projecting a glorious picture with no end to the bull run in sight, at least this year.

Stryker's Mobius Imaging Buyout to Boost Its Spine Division

Stryker (SYK) expects the buyout to remain neutral to its 2019 earnings.

Here's Why You Should Invest in Surmodics (SRDX) Stock Now

Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.